{"protocolSection":{"identificationModule":{"nctId":"NCT02503202","orgStudyIdInfo":{"id":"V920-012"},"secondaryIdInfos":[{"id":"2015-001658-14","type":"EUDRACT_NUMBER"},{"id":"V920-012","type":"OTHER","domain":"Merck Protocol Number"},{"id":"2015","type":"NIH","link":"https://reporter.nih.gov/quickSearch/2015"}],"organization":{"fullName":"Merck Sharp & Dohme LLC","class":"INDUSTRY"},"briefTitle":"Evaluation of the Safety and Immunogenicity of Three Consistency Lots and a High-Dose Lot of rVSV-ZEBOV-GP (V920 Ebola Vaccine) in Healthy Adults (V920-012)","officialTitle":"A Phase III, Randomized, Placebo-Controlled, Clinical Trial to Study the Safety and Immunogenicity of Three Consistency Lots and a High Dose Lot of rVSV-ZEBOV-GP (V920 Ebola Vaccine) in Healthy Adults"},"statusModule":{"statusVerifiedDate":"2018-10","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2015-08-17","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2016-05-02","type":"ACTUAL"},"completionDateStruct":{"date":"2017-09-29","type":"ACTUAL"},"studyFirstSubmitDate":"2015-07-17","studyFirstSubmitQcDate":"2015-07-17","studyFirstPostDateStruct":{"date":"2015-07-20","type":"ESTIMATED"},"resultsFirstSubmitDate":"2018-09-07","resultsFirstSubmitQcDate":"2018-10-09","resultsFirstPostDateStruct":{"date":"2018-10-12","type":"ACTUAL"},"lastUpdateSubmitDate":"2018-10-09","lastUpdatePostDateStruct":{"date":"2018-10-12","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Merck Sharp & Dohme LLC","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":false},"descriptionModule":{"briefSummary":"The study evaluated the safety and immunogenicity of 3 consistency lots and a high-dose lot of rVSV-ZEBOV-GP (V920 Ebola Vaccine) in healthy adults. The primary purpose of this study was to demonstrate consistency in the immune responses of participants receiving 3 separate lots of V920 through 28 days postvaccination. In addition to the 3 lot groups, a high-dose group and a placebo group were studied. A subset of participants representative of all treatment groups continued through 24 months postvaccination in the extension study for the evaluation of long-term safety. The primary hypothesis states that the geometric mean titer of anti-Zaire ebolavirus envelope (ZEBOV) glycoprotein antibody at 28 days postvaccination is equivalent across the three consistency lots."},"conditionsModule":{"conditions":["Prevention of Ebola Infection"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE3"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"PREVENTION","maskingInfo":{"masking":"TRIPLE","whoMasked":["PARTICIPANT","INVESTIGATOR","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":1197,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"V920 Consistency Lot A","type":"EXPERIMENTAL","description":"Participants received a 1.0 mL intramuscular injection of V920 on Day 1","interventionNames":["Biological: V920 Consistency Lot A"]},{"label":"V920 Consistency Lot B","type":"EXPERIMENTAL","description":"Participants received a 1.0 mL intramuscular injection of V920 on Day 1","interventionNames":["Biological: V920 Consistency Lot B"]},{"label":"V920 Consistency Lot C","type":"EXPERIMENTAL","description":"Participants received a 1.0 mL intramuscular injection of V920 on Day 1","interventionNames":["Biological: V920 Consistency Lot C"]},{"label":"V920 High-dose Lot","type":"EXPERIMENTAL","description":"Participants received a 1.0 mL intramuscular injection of V920 on Day 1","interventionNames":["Biological: V920 High-dose Lot"]},{"label":"Placebo to V920","type":"PLACEBO_COMPARATOR","description":"Participants received a 1.0 mL intramuscular injection of placebo on Day 1","interventionNames":["Biological: Placebo to V920"]}],"interventions":[{"type":"BIOLOGICAL","name":"V920 Consistency Lot A","description":"V920 (rVSV-ZEBOV-GP) Ebola Zaire vaccine consistency Lot A, live, attenuated, sterile solution for intramuscular injection","armGroupLabels":["V920 Consistency Lot A"]},{"type":"BIOLOGICAL","name":"V920 Consistency Lot B","description":"V920 (rVSV-ZEBOV-GP) Ebola Zaire vaccine consistency Lot B, live, attenuated, sterile solution for intramuscular injection","armGroupLabels":["V920 Consistency Lot B"]},{"type":"BIOLOGICAL","name":"V920 Consistency Lot C","description":"V920 (rVSV-ZEBOV-GP) Ebola Zaire vaccine consistency Lot C, live, attenuated, sterile solution for intramuscular injection","armGroupLabels":["V920 Consistency Lot C"]},{"type":"BIOLOGICAL","name":"V920 High-dose Lot","description":"V920 (rVSV-ZEBOV-GP) Ebola Zaire vaccine high-dose lot, live, attenuated, sterile solution for intramuscular injection","armGroupLabels":["V920 High-dose Lot"]},{"type":"BIOLOGICAL","name":"Placebo to V920","description":"Sodium chloride 0.9%, sterile solution for intramuscular injection","armGroupLabels":["Placebo to V920"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Geometric Mean Titer of Anti-ZEBOV Glycoprotein Antibody","description":"Serum was collected for determination of geometric mean titer (GMT) of anti-Zaire ebolavirus envelope (ZEBOV) glycoprotein antibodies using an enzyme-linked immunosorbent assay (GP-ELISA). The unit of measure is ELISA units/mL (EU/mL). The lower limit of quantification for the assay was 36.11 EU/mL.","timeFrame":"Day 28 postvaccination"},{"measure":"Percentage of Participants Reporting Serious Adverse Events","description":"An adverse event (AE) is defined as any untoward medical occurrence in a participant which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavourable and unintended sign, symptom, or disease temporally associated with the use of study vaccine or protocol-specified procedure, whether or not considered related to the study vaccine or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the use of the study vaccine or protocol-specified procedure is also an adverse event. A serious AE (SAE) is an AE that results in death, is life threatening, results in persistent or significant disability or incapacity, results in or prolongs a hospitalization, is a congenital anomaly or birth defect, is any other important medical event, is a cancer, or is associated with an overdose.","timeFrame":"Up to Month 6 postvaccination"},{"measure":"Percentage of Participants With Injection-site Adverse Events Prompted on the Vaccination Report Card","description":"An adverse event (AE) is defined as any untoward medical occurrence in a participant which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavourable and unintended sign, symptom, or disease temporally associated with the use of study vaccine or protocol-specified procedure, whether or not considered related to the study vaccine or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the use of the study vaccine or protocol-specified procedure is also an adverse event. Injection-site AEs prompted on the Vaccination Report Card (VRC) were erythema, pain, and swelling.","timeFrame":"Up to Day 5 postvaccination"},{"measure":"Percentage of Participants With Elevated Maximum Temperature","description":"Participants were instructed on the VRC to take and record their oral (or oral equivalent) temperature daily from the day of vaccination through Day 42. Elevated temperature was defined as ≥38.0° C (≥100.4° F).","timeFrame":"Up to Day 42 postvaccination"},{"measure":"Percentage of Participants With Arthralgia or Arthritis Adverse Events Prompted on the Vaccination Report Card","description":"An adverse event (AE) is defined as any untoward medical occurrence in a participant which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavourable and unintended sign, symptom, or disease temporally associated with the use of study vaccine or protocol-specified procedure, whether or not considered related to the study vaccine or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the use of the study vaccine or protocol-specified procedure is also an adverse event. Adverse events of arthralgia and arthritis were prompted on the VRC.","timeFrame":"From Day 5 to Day 42 postvaccination"},{"measure":"Percentage of Participants With Rash Adverse Events Prompted on the Vaccination Report Card","description":"An adverse event (AE) is defined as any untoward medical occurrence in a participant which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavourable and unintended sign, symptom, or disease temporally associated with the use of study vaccine or protocol-specified procedure, whether or not considered related to the study vaccine or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the use of the study vaccine or protocol-specified procedure is also an adverse event. Rash AEs prompted on the VRC were petechial rash, purpuric rash, and vesicular-type rash.","timeFrame":"Up to Day 42 postvaccination"},{"measure":"Percentage of Participants With Vesicular Lesion Adverse Events Prompted on the Vaccination Report Card","description":"An adverse event (AE) is defined as any untoward medical occurrence in a participant which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavourable and unintended sign, symptom, or disease temporally associated with the use of study vaccine or protocol-specified procedure, whether or not considered related to the study vaccine or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the use of the study vaccine or protocol-specified procedure is also an adverse event. Vesicular lesion AEs prompted on the VRC included blister and rash vesicular.","timeFrame":"Up to Day 42 postvaccination"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Not of reproductive potential, or of reproductive potential and agrees to avoid becoming pregnant or impregnating a partner for 2 months following study vaccination.\n\nExclusion Criteria:\n\n* Is currently participating in or has participated in an interventional clinical trial with an investigational compound or device within 90 days of participation in this trial.\n* Has previously been randomized in another clinical trial and received V920 or any other Ebola vaccine.\n* Has been exposed to Ebola virus at any time prior to study entry.\n* Is pregnant or breastfeeding or plans to conceive within 2 months following study vaccination.\n* Has direct household exposure to a pregnant or lactating woman at the time of participation in this trial.\n* Has had a fever (≥100.5ºF/38.0ºC) within 48 hours prior to study entry.\n* Has received systemic corticosteroids (equivalent of ≥2 mg/kg total daily dose of prednisone or ≥20 mg/day for persons weighing \\>10 kg) for ≥14 consecutive days and has not completed treatment at least 30 days prior to study entry.\n* Has received systemic corticosteroids exceeding physiologic replacement doses (\\~5 mg/day prednisone equivalent) within 14 days prior to study entry.\n* Has received any live virus vaccine within 30 days prior to study entry or any other (nonlive virus) vaccine within 14 days prior to study entry.\n* Has known or suspected impairment of immunological function (e.g., HIV positive).\n* Has direct household exposure to a person with known or suspected impairment of immunological function (e.g., HIV positive).\n* Has a clinically significant history of intravenous (IV) drug abuse within 12 months prior to study entry.\n* Has a known allergy/sensitivity or contraindication to investigational product(s) or its/their excipients (e.g., albumin).\n* Has a history of malignancy \\<=5 years prior to study entry except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer.\n* Is or has an immediate family member (e.g., spouse, parent/legal guardian, sibling or child) who is investigational site or sponsor staff directly involved with this trial.","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","maximumAge":"65 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Medical Director","affiliation":"Merck Sharp & Dohme LLC","role":"STUDY_DIRECTOR"}]},"referencesModule":{"references":[{"pmid":"28549145","type":"RESULT","citation":"Halperin SA, Arribas JR, Rupp R, Andrews CP, Chu L, Das R, Simon JK, Onorato MT, Liu K, Martin J, Helmond FA; V920-012 Study Team. Six-Month Safety Data of Recombinant Vesicular Stomatitis Virus-Zaire Ebola Virus Envelope Glycoprotein Vaccine in a Phase 3 Double-Blind, Placebo-Controlled Randomized Study in Healthy Adults. J Infect Dis. 2017 Jun 15;215(12):1789-1798. doi: 10.1093/infdis/jix189."},{"pmid":"33782211","type":"DERIVED","citation":"Grant-Klein RJ, Antonello J, Nichols R, Dubey S, Simon JK. Effects of Gamma Irradiation of Human Serum Samples from rVSVDeltaG-ZEBOV-GP (V920) Ebola Virus Vaccine Recipients on Plaque-Reduction Neutralization Assays. Am J Trop Med Hyg. 2021 Mar 29;104(5):1751-1754. doi: 10.4269/ajtmh.20-1055."},{"pmid":"31505665","type":"DERIVED","citation":"Halperin SA, Das R, Onorato MT, Liu K, Martin J, Grant-Klein RJ, Nichols R, Coller BA, Helmond FA, Simon JK; V920-012 Study Team. Immunogenicity, Lot Consistency, and Extended Safety of rVSVDeltaG-ZEBOV-GP Vaccine: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study in Healthy Adults. J Infect Dis. 2019 Aug 30;220(7):1127-1135. doi: 10.1093/infdis/jiz241."},{"pmid":"28647166","type":"DERIVED","citation":"Coller BG, Blue J, Das R, Dubey S, Finelli L, Gupta S, Helmond F, Grant-Klein RJ, Liu K, Simon J, Troth S, VanRheenen S, Waterbury J, Wivel A, Wolf J, Heppner DG, Kemp T, Nichols R, Monath TP. Clinical development of a recombinant Ebola vaccine in the midst of an unprecedented epidemic. Vaccine. 2017 Aug 16;35(35 Pt A):4465-4469. doi: 10.1016/j.vaccine.2017.05.097. Epub 2017 Jun 21."}]},"ipdSharingStatementModule":{"ipdSharing":"YES","description":"https://www.merck.com/clinical-trials/pdf/ProcedureAccessClinicalTrialData.pdf","url":"http://engagezone.msd.com/ds_documentation.php"}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"A total of 1261 participants were screened and 1197 were randomized.","groups":[{"id":"FG000","title":"V920 Consistency Lot A","description":"Participants received a 1.0-mL intramuscular injection of V920 consistency Lot A on Day 1"},{"id":"FG001","title":"V920 Consistency Lot B","description":"Participants received a 1.0-mL intramuscular injection of V920 consistency Lot B on Day 1"},{"id":"FG002","title":"V920 Consistency Lot C","description":"Participants received a 1.0-mL intramuscular injection of V920 consistency Lot C on Day 1"},{"id":"FG003","title":"V920 High-dose Lot","description":"Participants received a 1.0-mL intramuscular injection of V920 high-dose lot on Day 1"},{"id":"FG004","title":"Placebo","description":"Participants received a 1.0-mL intramuscular injection of placebo on Day 1"}],"periods":[{"title":"Base Study: Up to Month 6","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"266"},{"groupId":"FG001","numSubjects":"265"},{"groupId":"FG002","numSubjects":"267"},{"groupId":"FG003","numSubjects":"266"},{"groupId":"FG004","numSubjects":"133"}]},{"type":"Vaccinated","achievements":[{"groupId":"FG000","numSubjects":"266"},{"groupId":"FG001","numSubjects":"265"},{"groupId":"FG002","numSubjects":"266"},{"groupId":"FG003","numSubjects":"264"},{"groupId":"FG004","numSubjects":"133"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"248"},{"groupId":"FG001","numSubjects":"253"},{"groupId":"FG002","numSubjects":"252"},{"groupId":"FG003","numSubjects":"255"},{"groupId":"FG004","numSubjects":"130"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"18"},{"groupId":"FG001","numSubjects":"12"},{"groupId":"FG002","numSubjects":"15"},{"groupId":"FG003","numSubjects":"11"},{"groupId":"FG004","numSubjects":"3"}]}],"dropWithdraws":[{"type":"Death","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"11"},{"groupId":"FG001","numSubjects":"8"},{"groupId":"FG002","numSubjects":"10"},{"groupId":"FG003","numSubjects":"5"},{"groupId":"FG004","numSubjects":"1"}]},{"type":"Physician Decision","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"1"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"6"},{"groupId":"FG001","numSubjects":"3"},{"groupId":"FG002","numSubjects":"4"},{"groupId":"FG003","numSubjects":"4"},{"groupId":"FG004","numSubjects":"1"}]},{"type":"Randomized not vaccinated","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"2"},{"groupId":"FG004","numSubjects":"0"}]}]},{"title":"Extension: Month 6 to 24","milestones":[{"type":"STARTED","comment":"A subset of US participants enrolled in Extension Study","achievements":[{"groupId":"FG000","numSubjects":"119"},{"groupId":"FG001","numSubjects":"130"},{"groupId":"FG002","numSubjects":"112"},{"groupId":"FG003","numSubjects":"137"},{"groupId":"FG004","numSubjects":"68"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"108"},{"groupId":"FG001","numSubjects":"114"},{"groupId":"FG002","numSubjects":"103"},{"groupId":"FG003","numSubjects":"119"},{"groupId":"FG004","numSubjects":"67"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"11"},{"groupId":"FG001","numSubjects":"16"},{"groupId":"FG002","numSubjects":"9"},{"groupId":"FG003","numSubjects":"18"},{"groupId":"FG004","numSubjects":"1"}]}],"dropWithdraws":[{"type":"Protocol Violation","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"1"},{"groupId":"FG004","numSubjects":"0"}]},{"type":"Death","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"8"},{"groupId":"FG002","numSubjects":"6"},{"groupId":"FG003","numSubjects":"10"},{"groupId":"FG004","numSubjects":"1"}]},{"type":"Physician Decision","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"3"},{"groupId":"FG004","numSubjects":"0"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"5"},{"groupId":"FG001","numSubjects":"8"},{"groupId":"FG002","numSubjects":"2"},{"groupId":"FG003","numSubjects":"4"},{"groupId":"FG004","numSubjects":"0"}]}]}]},"baselineCharacteristicsModule":{"populationDescription":"All randomized participants","groups":[{"id":"BG000","title":"V920 Consistency Lot A","description":"Participants received a 1.0-mL intramuscular injection of V920 consistency Lot A on Day 1"},{"id":"BG001","title":"V920 Consistency Lot B","description":"Participants received a 1.0-mL intramuscular injection of V920 consistency Lot B on Day 1"},{"id":"BG002","title":"V920 Consistency Lot C","description":"Participants received a 1.0-mL intramuscular injection of V920 consistency Lot C on Day 1"},{"id":"BG003","title":"V920 High-dose Lot","description":"Participants received a 1.0-mL intramuscular injection of V920 high-dose lot on Day 1"},{"id":"BG004","title":"Placebo","description":"Participants received a 1.0-mL intramuscular injection of placebo on Day 1"},{"id":"BG005","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"266"},{"groupId":"BG001","value":"265"},{"groupId":"BG002","value":"267"},{"groupId":"BG003","value":"266"},{"groupId":"BG004","value":"133"},{"groupId":"BG005","value":"1197"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"Years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"41.3","spread":"13.4"},{"groupId":"BG001","value":"41.5","spread":"12.4"},{"groupId":"BG002","value":"40.9","spread":"13.1"},{"groupId":"BG003","value":"41.7","spread":"13.4"},{"groupId":"BG004","value":"41.1","spread":"13.7"},{"groupId":"BG005","value":"41.3","spread":"13.1"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"143"},{"groupId":"BG001","value":"135"},{"groupId":"BG002","value":"138"},{"groupId":"BG003","value":"149"},{"groupId":"BG004","value":"72"},{"groupId":"BG005","value":"637"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"123"},{"groupId":"BG001","value":"130"},{"groupId":"BG002","value":"129"},{"groupId":"BG003","value":"117"},{"groupId":"BG004","value":"61"},{"groupId":"BG005","value":"560"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Geometric Mean Titer of Anti-ZEBOV Glycoprotein Antibody","description":"Serum was collected for determination of geometric mean titer (GMT) of anti-Zaire ebolavirus envelope (ZEBOV) glycoprotein antibodies using an enzyme-linked immunosorbent assay (GP-ELISA). The unit of measure is ELISA units/mL (EU/mL). The lower limit of quantification for the assay was 36.11 EU/mL.","populationDescription":"Participants who were compliant with the protocol, received vaccination, were seronegative at Day 1, and had a serum sample collected within the acceptable day range","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"EU/mL","timeFrame":"Day 28 postvaccination","groups":[{"id":"OG000","title":"V920 Consistency Lot A","description":"Participants received a 1.0-mL intramuscular injection of V920 consistency Lot A on Day 1"},{"id":"OG001","title":"V920 Consistency Lot B","description":"Participants received a 1.0-mL intramuscular injection of V920 consistency Lot B on Day 1"},{"id":"OG002","title":"V920 Consistency Lot C","description":"Participants received a 1.0-mL intramuscular injection of V920 consistency Lot C on Day 1"},{"id":"OG003","title":"V920 High-dose Lot","description":"Participants received a 1.0-mL intramuscular injection of V920 high-dose lot on Day 1"},{"id":"OG004","title":"Placebo","description":"Participants received a 1.0-mL intramuscular injection of placebo on Day 1"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"239"},{"groupId":"OG001","value":"231"},{"groupId":"OG002","value":"226"},{"groupId":"OG003","value":"219"},{"groupId":"OG004","value":"124"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1183.9","lowerLimit":"1038.7","upperLimit":"1349.4"},{"groupId":"OG001","value":"1266.0","lowerLimit":"1108.2","upperLimit":"1446.2"},{"groupId":"OG002","value":"1346.0","lowerLimit":"1176.6","upperLimit":"1539.9"},{"groupId":"OG003","value":"1291.9","lowerLimit":"1126.9","upperLimit":"1481.2"},{"groupId":"OG004","value":"NA","lowerLimit":"NA","upperLimit":"NA","comment":"Geometric Mean and CIs are \\<36.11 EU/mL"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"EQUIVALENCE","nonInferiorityComment":"Lot consistency requires the 95% confidence interval of the GMT ratio of \\>0.5 and ≤2.0 for the primary analysis and \\>0.67 and ≤1.5 for the secondary analysis.","pValue":"<0.001","pValueComment":"Primary analysis: a p-value \\<0.025 supported the conclusion of equivalence. If equivalence was established for the 3 pairwise comparisons, the lots would be considered to be consistent.","statisticalMethod":"ANOVA","paramType":"GMT ratio (Lot A / Lot B)","paramValue":"0.94","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.77","ciUpperLimit":"1.14"},{"groupIds":["OG000","OG002"],"nonInferiorityType":"EQUIVALENCE","nonInferiorityComment":"Lot consistency requires the 95% confidence interval of the GMT ratio of \\>0.5 and ≤2.0 for the primary analysis and \\>0.67 and ≤1.5 for the secondary analysis.","pValue":"<0.001","pValueComment":"Primary analysis: a p-value \\<0.025 supported the conclusion of equivalence. If equivalence was established for the 3 pairwise comparisons, the lots would be considered to be consistent.","statisticalMethod":"ANOVA","paramType":"GMT ratio (Lot A / Lot C)","paramValue":"0.88","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.71","ciUpperLimit":"1.09"},{"groupIds":["OG001","OG002"],"nonInferiorityType":"EQUIVALENCE","nonInferiorityComment":"Lot consistency requires the 95% confidence interval of the GMT ratio of \\>0.5 and ≤2.0 for the primary analysis and \\>0.67 and ≤1.5 for the secondary analysis.","pValue":"<0.001","pValueComment":"Primary analysis: a p-value \\<0.025 supported the conclusion of equivalence. If equivalence was established for the 3 pairwise comparisons, the lots would be considered to be consistent.","statisticalMethod":"ANOVA","paramType":"GMT ratio (Lot B / Lot C)","paramValue":"0.94","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.77","ciUpperLimit":"1.15"}]},{"type":"PRIMARY","title":"Percentage of Participants Reporting Serious Adverse Events","description":"An adverse event (AE) is defined as any untoward medical occurrence in a participant which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavourable and unintended sign, symptom, or disease temporally associated with the use of study vaccine or protocol-specified procedure, whether or not considered related to the study vaccine or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the use of the study vaccine or protocol-specified procedure is also an adverse event. A serious AE (SAE) is an AE that results in death, is life threatening, results in persistent or significant disability or incapacity, results in or prolongs a hospitalization, is a congenital anomaly or birth defect, is any other important medical event, is a cancer, or is associated with an overdose.","populationDescription":"Randomized participants who received vaccination and had follow-up data for the outcome measure","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of participants","timeFrame":"Up to Month 6 postvaccination","groups":[{"id":"OG000","title":"V920 Consistency Lot A","description":"Participants received a 1.0-mL intramuscular injection of V920 consistency Lot A on Day 1"},{"id":"OG001","title":"V920 Consistency Lot B","description":"Participants received a 1.0-mL intramuscular injection of V920 consistency Lot B on Day 1"},{"id":"OG002","title":"V920 Consistency Lot C","description":"Participants received a 1.0-mL intramuscular injection of V920 consistency Lot C on Day 1"},{"id":"OG003","title":"V920 High-dose Lot","description":"Participants received a 1.0-mL intramuscular injection of V920 high-dose lot on Day 1"},{"id":"OG004","title":"Placebo","description":"Participants received a 1.0-mL intramuscular injection of placebo on Day 1"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"265"},{"groupId":"OG001","value":"263"},{"groupId":"OG002","value":"263"},{"groupId":"OG003","value":"260"},{"groupId":"OG004","value":"133"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.6"},{"groupId":"OG001","value":"1.5"},{"groupId":"OG002","value":"2.7"},{"groupId":"OG003","value":"1.2"},{"groupId":"OG004","value":"0.0"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","pValue":"0.368","statisticalMethod":"Miettinen & Nurminen","paramType":"Risk Difference (RD)","paramValue":"1.1","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-1.5","ciUpperLimit":"4.0","estimateComment":"Risk difference is Lot A - Lot B"},{"groupIds":["OG000","OG002"],"nonInferiorityType":"OTHER","pValue":"0.989","statisticalMethod":"Miettinen & Nurminen","paramType":"Risk Difference (RD)","paramValue":"-0.0","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-3.1","ciUpperLimit":"3.0","estimateComment":"Risk difference is Lot A - Lot C"},{"groupIds":["OG001","OG002"],"nonInferiorityType":"OTHER","pValue":"0.361","statisticalMethod":"Miettinen & Nurminen","paramType":"Risk Difference (RD)","paramValue":"-1.1","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-4.1","ciUpperLimit":"1.5","estimateComment":"Risk difference is Lot B - Lot C"},{"groupIds":["OG003","OG004"],"nonInferiorityType":"OTHER","pValue":"0.214","statisticalMethod":"Miettinen & Nurminen","paramType":"Risk Difference (RD)","paramValue":"1.2","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-1.7","ciUpperLimit":"3.3","estimateComment":"Risk difference is High-dose Lot - Placebo"}]},{"type":"PRIMARY","title":"Percentage of Participants With Injection-site Adverse Events Prompted on the Vaccination Report Card","description":"An adverse event (AE) is defined as any untoward medical occurrence in a participant which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavourable and unintended sign, symptom, or disease temporally associated with the use of study vaccine or protocol-specified procedure, whether or not considered related to the study vaccine or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the use of the study vaccine or protocol-specified procedure is also an adverse event. Injection-site AEs prompted on the Vaccination Report Card (VRC) were erythema, pain, and swelling.","populationDescription":"Randomized participants who received vaccination and had follow-up data for the outcome measure","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of participants","timeFrame":"Up to Day 5 postvaccination","groups":[{"id":"OG000","title":"V920 Consistency Lot A","description":"Participants received a 1.0-mL intramuscular injection of V920 consistency Lot A on Day 1"},{"id":"OG001","title":"V920 Consistency Lot B","description":"Participants received a 1.0-mL intramuscular injection of V920 consistency Lot B on Day 1"},{"id":"OG002","title":"V920 Consistency Lot C","description":"Participants received a 1.0-mL intramuscular injection of V920 consistency Lot C on Day 1"},{"id":"OG003","title":"V920 High-dose Lot","description":"Participants received a 1.0-mL intramuscular injection of V920 high-dose lot on Day 1"},{"id":"OG004","title":"Placebo","description":"Participants received a 1.0-mL intramuscular injection of placebo on Day 1"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"265"},{"groupId":"OG001","value":"263"},{"groupId":"OG002","value":"263"},{"groupId":"OG003","value":"260"},{"groupId":"OG004","value":"133"}]}],"classes":[{"title":"Injection-site erythema","categories":[{"measurements":[{"groupId":"OG000","value":"14.7"},{"groupId":"OG001","value":"10.6"},{"groupId":"OG002","value":"14.8"},{"groupId":"OG003","value":"7.3"},{"groupId":"OG004","value":"1.5"}]}]},{"title":"Injection-site pain","categories":[{"measurements":[{"groupId":"OG000","value":"66.8"},{"groupId":"OG001","value":"73.0"},{"groupId":"OG002","value":"70.3"},{"groupId":"OG003","value":"67.7"},{"groupId":"OG004","value":"12.8"}]}]},{"title":"Injection-site swelling","categories":[{"measurements":[{"groupId":"OG000","value":"17.7"},{"groupId":"OG001","value":"13.7"},{"groupId":"OG002","value":"18.3"},{"groupId":"OG003","value":"16.2"},{"groupId":"OG004","value":"3.0"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Injection site erythema","nonInferiorityType":"OTHER","pValue":"0.160","statisticalMethod":"Miettinen & Nurminen","paramType":"Risk Difference (RD)","paramValue":"4.1","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-1.6","ciUpperLimit":"9.9","estimateComment":"Risk difference is Lot A - Lot B"},{"groupIds":["OG000","OG002"],"groupDescription":"Injection site erythema","nonInferiorityType":"OTHER","pValue":"0.971","statisticalMethod":"Miettinen & Nurminen","paramType":"Risk Difference (RD)","paramValue":"-0.1","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-6.2","ciUpperLimit":"6.0","estimateComment":"Risk difference is Lot A - Lot C"},{"groupIds":["OG001","OG002"],"groupDescription":"Injection site erythema","nonInferiorityType":"OTHER","pValue":"0.151","statisticalMethod":"Miettinen & Nurminen","paramType":"Risk Difference (RD)","paramValue":"-4.2","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-10.0","ciUpperLimit":"1.5","estimateComment":"Risk difference is Lot B - Lot C"},{"groupIds":["OG003","OG004"],"groupDescription":"Injection site erythema","nonInferiorityType":"OTHER","pValue":"0.016","statisticalMethod":"Miettinen & Nurminen","paramType":"Risk Difference (RD)","paramValue":"5.8","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"1.4","ciUpperLimit":"9.9","estimateComment":"Risk difference is High-dose Lot - Placebo"},{"groupIds":["OG000","OG001"],"groupDescription":"Injection site pain","nonInferiorityType":"OTHER","pValue":"0.120","statisticalMethod":"Miettinen & Nurminen","paramType":"Risk Difference (RD)","paramValue":"-6.2","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-14.0","ciUpperLimit":"1.6","estimateComment":"Risk difference is Lot A - Lot B"},{"groupIds":["OG000","OG002"],"groupDescription":"Injection site pain","nonInferiorityType":"OTHER","pValue":"0.380","statisticalMethod":"Miettinen & Nurminen","paramType":"Risk Difference (RD)","paramValue":"-3.5","ciPctValue":"94","ciNumSides":"TWO_SIDED","ciLowerLimit":"-11.4","ciUpperLimit":"4.4","estimateComment":"Risk difference is Lot A - Lot C"},{"groupIds":["OG001","OG002"],"groupDescription":"Injection site pain","nonInferiorityType":"OTHER","pValue":"0.499","statisticalMethod":"Miettinen & Nurminen","paramType":"Risk Difference (RD)","paramValue":"2.7","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-5.1","ciUpperLimit":"10.4","estimateComment":"Risk difference is Lot B - Lot C"},{"groupIds":["OG003","OG004"],"groupDescription":"Injection site pain","nonInferiorityType":"OTHER","pValue":"<0.001","statisticalMethod":"Miettinen & Nurminen","paramType":"Risk Difference (RD)","paramValue":"54.9","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"46.2","ciUpperLimit":"62.3","estimateComment":"Risk difference is High-dose Lot - Placebo"},{"groupIds":["OG000","OG001"],"groupDescription":"Injection site swelling","nonInferiorityType":"OTHER","pValue":"0.202","statisticalMethod":"Miettinen & Nurminen","paramType":"Risk Difference (RD)","paramValue":"4.0","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-2.2","ciUpperLimit":"10.3","estimateComment":"Risk difference is Lot A - Lot B"},{"groupIds":["OG000","OG002"],"groupDescription":"Injection site swelling","nonInferiorityType":"OTHER","pValue":"0.878","statisticalMethod":"Miettinen & Nurminen","paramType":"Risk Difference (RD)","paramValue":"-0.5","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-7.1","ciUpperLimit":"6.1","estimateComment":"Risk difference is Lot A - Lot C"},{"groupIds":["OG001","OG002"],"groupDescription":"Injection site swelling","nonInferiorityType":"OTHER","pValue":"0.154","statisticalMethod":"Miettinen & Nurminen","paramType":"Risk Difference (RD)","paramValue":"-4.6","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-10.9","ciUpperLimit":"1.7","estimateComment":"Risk difference is Lot B - Lot C"},{"groupIds":["OG003","OG004"],"groupDescription":"Injection site swelling","nonInferiorityType":"OTHER","pValue":"<0.001","statisticalMethod":"Miettinen & Nurminen","paramType":"Risk Difference (RD)","paramValue":"13.1","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"7.4","ciUpperLimit":"18.6","estimateComment":"Risk difference is High-dose Lot - Placebo"}]},{"type":"PRIMARY","title":"Percentage of Participants With Elevated Maximum Temperature","description":"Participants were instructed on the VRC to take and record their oral (or oral equivalent) temperature daily from the day of vaccination through Day 42. Elevated temperature was defined as ≥38.0° C (≥100.4° F).","populationDescription":"Randomized participants who received vaccination and had follow-up data for the outcome measure","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of participants","timeFrame":"Up to Day 42 postvaccination","groups":[{"id":"OG000","title":"V920 Consistency Lot A","description":"Participants received a 1.0-mL intramuscular injection of V920 consistency Lot A on Day 1"},{"id":"OG001","title":"V920 Consistency Lot B","description":"Participants received a 1.0-mL intramuscular injection of V920 consistency Lot B on Day 1"},{"id":"OG002","title":"V920 Consistency Lot C","description":"Participants received a 1.0-mL intramuscular injection of V920 consistency Lot C on Day 1"},{"id":"OG003","title":"V920 High-dose Lot","description":"Participants received a 1.0-mL intramuscular injection of V920 high-dose lot on Day 1"},{"id":"OG004","title":"Placebo","description":"Participants received a 1.0-mL intramuscular injection of placebo on Day 1"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"262"},{"groupId":"OG001","value":"263"},{"groupId":"OG002","value":"263"},{"groupId":"OG003","value":"258"},{"groupId":"OG004","value":"132"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"21.4"},{"groupId":"OG001","value":"16.7"},{"groupId":"OG002","value":"22.4"},{"groupId":"OG003","value":"32.2"},{"groupId":"OG004","value":"0.8"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","pValue":"0.176","statisticalMethod":"Miettinen & Nurminen","paramType":"Risk Difference (RD)","paramValue":"4.6","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-2.1","ciUpperLimit":"11.4","estimateComment":"Risk difference is Lot A - Lot B"},{"groupIds":["OG000","OG002"],"nonInferiorityType":"OTHER","pValue":"0.769","statisticalMethod":"Miettinen & Nurminen","paramType":"Risk Difference (RD)","paramValue":"-1.1","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-8.2","ciUpperLimit":"6.0","estimateComment":"Risk difference is Lot A - Lot C"},{"groupIds":["OG001","OG002"],"nonInferiorityType":"OTHER","pValue":"0.100","statisticalMethod":"Miettinen & Nurminen","paramType":"Risk Difference (RD)","paramValue":"-5.7","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-12.5","ciUpperLimit":"1.1","estimateComment":"Risk difference is Lot B - Lot C"},{"groupIds":["OG003","OG004"],"nonInferiorityType":"OTHER","pValue":"<0.001","statisticalMethod":"Miettinen & Nurminen","paramType":"Risk Difference (RD)","paramValue":"31.4","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"25.6","ciUpperLimit":"37.5","estimateComment":"Risk difference is High-dose Lot - Placebo"}]},{"type":"PRIMARY","title":"Percentage of Participants With Arthralgia or Arthritis Adverse Events Prompted on the Vaccination Report Card","description":"An adverse event (AE) is defined as any untoward medical occurrence in a participant which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavourable and unintended sign, symptom, or disease temporally associated with the use of study vaccine or protocol-specified procedure, whether or not considered related to the study vaccine or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the use of the study vaccine or protocol-specified procedure is also an adverse event. Adverse events of arthralgia and arthritis were prompted on the VRC.","populationDescription":"Randomized participants who received vaccination and had follow-up data for the outcome measure","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of participants","timeFrame":"From Day 5 to Day 42 postvaccination","groups":[{"id":"OG000","title":"V920 Consistency Lot A","description":"Participants received a 1.0-mL intramuscular injection of V920 consistency Lot A on Day 1"},{"id":"OG001","title":"V920 Consistency Lot B","description":"Participants received a 1.0-mL intramuscular injection of V920 consistency Lot B on Day 1"},{"id":"OG002","title":"V920 Consistency Lot C","description":"Participants received a 1.0-mL intramuscular injection of V920 consistency Lot C on Day 1"},{"id":"OG003","title":"V920 High-dose Lot","description":"Participants received a 1.0-mL intramuscular injection of V920 high-dose lot on Day 1"},{"id":"OG004","title":"Placebo","description":"Participants received a 1.0-mL intramuscular injection of placebo on Day 1"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"265"},{"groupId":"OG001","value":"263"},{"groupId":"OG002","value":"263"},{"groupId":"OG003","value":"260"},{"groupId":"OG004","value":"133"}]}],"classes":[{"title":"Arthralgia AEs","categories":[{"measurements":[{"groupId":"OG000","value":"5.7"},{"groupId":"OG001","value":"5.7"},{"groupId":"OG002","value":"6.5"},{"groupId":"OG003","value":"7.7"},{"groupId":"OG004","value":"1.5"}]}]},{"title":"Arthritis AEs","categories":[{"measurements":[{"groupId":"OG000","value":"4.5"},{"groupId":"OG001","value":"3.8"},{"groupId":"OG002","value":"2.7"},{"groupId":"OG003","value":"3.1"},{"groupId":"OG004","value":"0.0"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Arthralgia","nonInferiorityType":"OTHER","pValue":"0.983","statisticalMethod":"Miettinen & Nurminen","paramType":"Risk Difference (RD)","paramValue":"-0.0","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-4.2","ciUpperLimit":"4.1","estimateComment":"Risk difference is Lot A - Lot B"},{"groupIds":["OG000","OG002"],"groupDescription":"Arthralgia","nonInferiorityType":"OTHER","pValue":"0.699","statisticalMethod":"Miettinen & Nurminen","paramType":"Risk Difference (RD)","paramValue":"-0.8","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-5.1","ciUpperLimit":"3.4","estimateComment":"Risk difference is Lot A - Lot C"},{"groupIds":["OG001","OG002"],"groupDescription":"Arthralgia","nonInferiorityType":"OTHER","pValue":"0.716","statisticalMethod":"Miettinen & Nurminen","paramType":"Risk Difference (RD)","paramValue":"-0.8","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-5.1","ciUpperLimit":"3.5","estimateComment":"Risk difference is Lot B - Lot C"},{"groupIds":["OG003","OG004"],"groupDescription":"Arthralgia","nonInferiorityType":"OTHER","pValue":"0.012","statisticalMethod":"Miettinen & Nurminen","paramType":"Risk Difference (RD)","paramValue":"6.2","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"1.8","ciUpperLimit":"10.4","estimateComment":"Risk difference is High-dose Lot - Placebo"},{"groupIds":["OG000","OG001"],"groupDescription":"Arthritis","nonInferiorityType":"OTHER","pValue":"0.677","statisticalMethod":"Miettinen & Nurminen","paramType":"Risk Difference (RD)","paramValue":"0.7","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-2.9","ciUpperLimit":"4.4","estimateComment":"Risk difference is Lot A - Lot B"},{"groupIds":["OG000","OG002"],"groupDescription":"Arthritis","nonInferiorityType":"OTHER","pValue":"0.250","statisticalMethod":"Miettinen & Nurminen","paramType":"Risk Difference (RD)","paramValue":"1.9","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-1.4","ciUpperLimit":"5.4","estimateComment":"Risk difference is Lot A - Lot C"},{"groupIds":["OG001","OG002"],"groupDescription":"Arthritis","nonInferiorityType":"OTHER","pValue":"0.460","statisticalMethod":"Miettinen & Nurminen","paramType":"Risk Difference (RD)","paramValue":"1.1","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-2.1","ciUpperLimit":"4.5","estimateComment":"Risk difference is Lot B - Lot C"},{"groupIds":["OG003","OG004"],"groupDescription":"Arthritis","nonInferiorityType":"OTHER","pValue":"0.041","statisticalMethod":"Miettinen & Nurminen","paramType":"Risk Difference (RD)","paramValue":"3.1","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.2","ciUpperLimit":"6.0","estimateComment":"Risk difference is High-dose Lot - Placebo"}]},{"type":"PRIMARY","title":"Percentage of Participants With Rash Adverse Events Prompted on the Vaccination Report Card","description":"An adverse event (AE) is defined as any untoward medical occurrence in a participant which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavourable and unintended sign, symptom, or disease temporally associated with the use of study vaccine or protocol-specified procedure, whether or not considered related to the study vaccine or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the use of the study vaccine or protocol-specified procedure is also an adverse event. Rash AEs prompted on the VRC were petechial rash, purpuric rash, and vesicular-type rash.","populationDescription":"Randomized participants who received vaccination and had follow-up data for the outcome measure","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of participants","timeFrame":"Up to Day 42 postvaccination","groups":[{"id":"OG000","title":"V920 Consistency Lot A","description":"Participants received a 1.0-mL intramuscular injection of V920 consistency Lot A on Day 1"},{"id":"OG001","title":"V920 Consistency Lot B","description":"Participants received a 1.0-mL intramuscular injection of V920 consistency Lot B on Day 1"},{"id":"OG002","title":"V920 Consistency Lot C","description":"Participants received a 1.0-mL intramuscular injection of V920 consistency Lot C on Day 1"},{"id":"OG003","title":"V920 High-dose Lot","description":"Participants received a 1.0-mL intramuscular injection of V920 high-dose lot on Day 1"},{"id":"OG004","title":"Placebo","description":"Participants received a 1.0-mL intramuscular injection of placebo on Day 1"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"265"},{"groupId":"OG001","value":"263"},{"groupId":"OG002","value":"263"},{"groupId":"OG003","value":"260"},{"groupId":"OG004","value":"133"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.0"},{"groupId":"OG001","value":"4.6"},{"groupId":"OG002","value":"3.8"},{"groupId":"OG003","value":"3.8"},{"groupId":"OG004","value":"1.5"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","pValue":"0.353","statisticalMethod":"Miettinen & Nurminen","paramType":"Risk Difference (RD)","paramValue":"-1.5","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-5.1","ciUpperLimit":"1.9","estimateComment":"Risk difference is Lot A - Lot B"},{"groupIds":["OG000","OG002"],"nonInferiorityType":"OTHER","pValue":"0.620","statisticalMethod":"Miettinen & Nurminen","paramType":"Risk Difference (RD)","paramValue":"-0.8","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-4.2","ciUpperLimit":"2.5","estimateComment":"Risk difference is Lot A - Lot C"},{"groupIds":["OG001","OG002"],"nonInferiorityType":"OTHER","pValue":"0.663","statisticalMethod":"Miettinen & Nurminen","paramType":"Risk Difference (RD)","paramValue":"0.8","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-2.9","ciUpperLimit":"4.5","estimateComment":"Risk difference is Lot B - Lot C"},{"groupIds":["OG003","OG004"],"nonInferiorityType":"OTHER","pValue":"0.202","statisticalMethod":"Miettinen & Nurminen","paramType":"Risk Difference (RD)","paramValue":"2.3","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-1.8","ciUpperLimit":"5.7","estimateComment":"Risk difference is High-dose Lot - Placebo"}]},{"type":"PRIMARY","title":"Percentage of Participants With Vesicular Lesion Adverse Events Prompted on the Vaccination Report Card","description":"An adverse event (AE) is defined as any untoward medical occurrence in a participant which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavourable and unintended sign, symptom, or disease temporally associated with the use of study vaccine or protocol-specified procedure, whether or not considered related to the study vaccine or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the use of the study vaccine or protocol-specified procedure is also an adverse event. Vesicular lesion AEs prompted on the VRC included blister and rash vesicular.","populationDescription":"Randomized participants who received vaccination and had follow-up data for the outcome measure","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of participants","timeFrame":"Up to Day 42 postvaccination","groups":[{"id":"OG000","title":"V920 Consistency Lot A","description":"Participants received a 1.0-mL intramuscular injection of V920 consistency Lot A on Day 1"},{"id":"OG001","title":"V920 Consistency Lot B","description":"Participants received a 1.0-mL intramuscular injection of V920 consistency Lot B on Day 1"},{"id":"OG002","title":"V920 Consistency Lot C","description":"Participants received a 1.0-mL intramuscular injection of V920 consistency Lot C on Day 1"},{"id":"OG003","title":"V920 High-dose Lot","description":"Participants received a 1.0-mL intramuscular injection of V920 high-dose lot on Day 1"},{"id":"OG004","title":"Placebo","description":"Participants received a 1.0-mL intramuscular injection of placebo on Day 1"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"265"},{"groupId":"OG001","value":"263"},{"groupId":"OG002","value":"263"},{"groupId":"OG003","value":"260"},{"groupId":"OG004","value":"133"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.9"},{"groupId":"OG001","value":"1.1"},{"groupId":"OG002","value":"1.5"},{"groupId":"OG003","value":"1.5"},{"groupId":"OG004","value":"0.0"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","pValue":"0.483","statisticalMethod":"Miettinen & Nurminen","paramType":"Risk Difference (RD)","paramValue":"0.7","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-1.6","ciUpperLimit":"3.3","estimateComment":"Risk difference is Lot A - Lot B"},{"groupIds":["OG000","OG002"],"nonInferiorityType":"OTHER","pValue":"0.746","statisticalMethod":"Miettinen & Nurminen","paramType":"Risk Difference (RD)","paramValue":"0.4","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-2.2","ciUpperLimit":"3.0","estimateComment":"Risk difference is Lot A - Lot C"},{"groupIds":["OG001","OG002"],"nonInferiorityType":"OTHER","pValue":"0.704","statisticalMethod":"Miettinen & Nurminen","paramType":"Risk Difference (RD)","paramValue":"-0.4","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-2.8","ciUpperLimit":"2.0","estimateComment":"Risk difference is Lot B - Lot C"},{"groupIds":["OG003","OG004"],"nonInferiorityType":"OTHER","pValue":"0.151","statisticalMethod":"Miettinen & Nurminen","paramType":"Risk Difference (RD)","paramValue":"1.5","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-1.3","ciUpperLimit":"3.9","estimateComment":"Risk difference is High-dose Lot - Placebo"}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"Up to Month 24","description":"The at-risk population was randomized participants who received vaccination and had follow-up safety data available.","eventGroups":[{"id":"EG000","title":"V920 Consistency Lot A","description":"Participants received a 1.0-mL intramuscular injection of V920 consistency Lot A on Day 1","deathsNumAffected":2,"deathsNumAtRisk":265,"seriousNumAffected":12,"seriousNumAtRisk":265,"otherNumAffected":211,"otherNumAtRisk":265},{"id":"EG001","title":"V920 Consistency Lot B","description":"Participants received a 1.0-mL intramuscular injection of V920 consistency Lot B on Day 1","deathsNumAffected":1,"deathsNumAtRisk":263,"seriousNumAffected":12,"seriousNumAtRisk":263,"otherNumAffected":211,"otherNumAtRisk":263},{"id":"EG002","title":"V920 Consistency Lot C","description":"Participants received a 1.0-mL intramuscular injection of V920 consistency Lot C on Day 1","deathsNumAffected":0,"deathsNumAtRisk":263,"seriousNumAffected":11,"seriousNumAtRisk":263,"otherNumAffected":208,"otherNumAtRisk":263},{"id":"EG003","title":"V920 High-dose Lot","description":"Participants received a 1.0-mL intramuscular injection of V920 high-dose lot on Day 1","deathsNumAffected":0,"deathsNumAtRisk":260,"seriousNumAffected":8,"seriousNumAtRisk":260,"otherNumAffected":208,"otherNumAtRisk":260},{"id":"EG004","title":"Placebo","description":"Participants received a 1.0-mL intramuscular injection of placebo on Day 1","deathsNumAffected":0,"deathsNumAtRisk":133,"seriousNumAffected":4,"seriousNumAtRisk":133,"otherNumAffected":35,"otherNumAtRisk":133}],"seriousEvents":[{"term":"Conductive deafness","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA version 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":265},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":263},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":263},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":260},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":133}]},{"term":"Autoimmune thyroiditis","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA version 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":265},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":263},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":263},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":260},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":133}]},{"term":"Hyperthyroidism","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA version 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":265},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":263},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":263},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":260},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":133}]},{"term":"Abdominal incarcerated hernia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA version 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":265},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":263},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":263},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":260},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":133}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA version 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":265},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":263},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":263},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":260},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":133}]},{"term":"Gastrointestinal disorder","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA version 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":265},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":263},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":263},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":260},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":133}]},{"term":"Gastrooesophageal reflux disease","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA version 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":265},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":263},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":263},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":260},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":133}]},{"term":"Incarcerated umbilical hernia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA version 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":265},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":263},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":263},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":260},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":133}]},{"term":"Cholecystitis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA version 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":265},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":263},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":263},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":260},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":133}]},{"term":"Hepatic failure","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA version 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":265},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":263},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":263},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":260},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":133}]},{"term":"Appendicitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":265},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":263},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":263},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":260},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":133}]},{"term":"Cellulitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":265},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":263},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":263},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":260},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":133}]},{"term":"Clostridium difficile infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":265},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":263},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":263},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":260},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":133}]},{"term":"Diverticulitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":265},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":263},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":263},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":260},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":133}]},{"term":"Mastitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":265},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":263},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":263},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":260},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":133}]},{"term":"Meningitis aseptic","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":265},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":263},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":263},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":260},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":133}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":265},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":263},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":263},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":260},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":133}]},{"term":"Upper respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":265},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":263},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":263},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":260},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":133}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":265},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":263},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":263},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":260},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":133}]},{"term":"Animal bite","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA version 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":265},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":263},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":263},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":260},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":133}]},{"term":"Arthropod bite","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA version 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":265},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":263},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":263},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":260},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":133}]},{"term":"Craniocerebral injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA version 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":265},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":263},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":263},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":260},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":133}]},{"term":"Femur fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA version 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":265},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":263},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":263},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":260},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":133}]},{"term":"Rib fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA version 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":265},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":263},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":263},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":260},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":133}]},{"term":"Road traffic accident","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA version 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":265},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":263},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":263},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":260},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":133}]},{"term":"Scapula fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA version 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":265},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":263},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":263},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":260},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":133}]},{"term":"Platelet count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA version 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":265},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":263},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":263},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":260},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":133}]},{"term":"Hyperglycaemic hyperosmolar nonketotic syndrome","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA version 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":265},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":263},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":263},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":260},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":133}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA version 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":265},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":263},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":263},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":260},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":133}]},{"term":"Exostosis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA version 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":265},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":263},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":263},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":260},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":133}]},{"term":"Foot deformity","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA version 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":265},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":263},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":263},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":260},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":133}]},{"term":"Musculoskeletal chest pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA version 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":265},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":263},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":263},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":260},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":133}]},{"term":"Spinal column stenosis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA version 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":265},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":263},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":263},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":260},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":133}]},{"term":"Basal cell carcinoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA version 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":265},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":263},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":263},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":260},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":133}]},{"term":"Breast cancer","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA version 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":265},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":263},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":263},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":260},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":133}]},{"term":"Breast cancer stage III","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA version 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":265},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":263},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":263},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":260},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":133}]},{"term":"Oropharyngeal squamous cell carcinoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA version 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":265},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":263},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":263},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":260},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":133}]},{"term":"Migraine","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA version 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":265},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":263},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":263},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":260},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":133}]},{"term":"Radicular pain","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA version 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":265},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":263},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":263},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":260},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":133}]},{"term":"Abortion spontaneous","organSystem":"Pregnancy, puerperium and perinatal conditions","sourceVocabulary":"MedDRA version 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":265},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":263},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":263},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":260},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":133}]},{"term":"Ruptured ectopic pregnancy","organSystem":"Pregnancy, puerperium and perinatal conditions","sourceVocabulary":"MedDRA version 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":265},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":263},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":263},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":260},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":133}]},{"term":"Schizophrenia","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA version 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":265},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":263},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":263},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":260},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":133}]},{"term":"Suicidal ideation","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA version 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":265},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":263},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":263},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":260},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":133}]},{"term":"Nephrolithiasis","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA version 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":265},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":263},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":263},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":260},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":133}]},{"term":"Renal failure","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA version 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":265},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":263},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":263},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":260},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":133}]},{"term":"Menometrorrhagia","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA version 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":265},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":263},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":263},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":260},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":133}]},{"term":"Asthma","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA version 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":265},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":263},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":263},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":260},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":133}]},{"term":"Haemothorax","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA version 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":265},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":263},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":263},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":260},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":133}]},{"term":"Hypoxia","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA version 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":265},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":263},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":263},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":260},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":133}]},{"term":"Pneumothorax","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA version 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":265},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":263},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":263},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":260},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":133}]},{"term":"Pulmonary embolism","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA version 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":265},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":263},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":263},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":260},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":133}]},{"term":"Respiratory failure","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA version 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":265},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":263},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":263},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":260},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":133}]},{"term":"Angioedema","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA version 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":265},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":263},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":263},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":260},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":133}]},{"term":"Deep vein thrombosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA version 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":265},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":263},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":263},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":260},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":133}]},{"term":"Hypertension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA version 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":265},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":263},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":263},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":260},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":133}]}],"otherEvents":[{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA version 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":12,"numAffected":12,"numAtRisk":265},{"groupId":"EG001","numEvents":13,"numAffected":13,"numAtRisk":263},{"groupId":"EG002","numEvents":16,"numAffected":15,"numAtRisk":263},{"groupId":"EG003","numEvents":15,"numAffected":14,"numAtRisk":260},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":133}]},{"term":"Chills","organSystem":"General disorders","sourceVocabulary":"MedDRA version 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":14,"numAffected":14,"numAtRisk":265},{"groupId":"EG001","numEvents":16,"numAffected":16,"numAtRisk":263},{"groupId":"EG002","numEvents":20,"numAffected":20,"numAtRisk":263},{"groupId":"EG003","numEvents":27,"numAffected":27,"numAtRisk":260},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":133}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA version 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":22,"numAffected":21,"numAtRisk":265},{"groupId":"EG001","numEvents":15,"numAffected":15,"numAtRisk":263},{"groupId":"EG002","numEvents":9,"numAffected":9,"numAtRisk":263},{"groupId":"EG003","numEvents":21,"numAffected":20,"numAtRisk":260},{"groupId":"EG004","numEvents":3,"numAffected":3,"numAtRisk":133}]},{"term":"Influenza like illness","organSystem":"General disorders","sourceVocabulary":"MedDRA version 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":14,"numAffected":14,"numAtRisk":265},{"groupId":"EG001","numEvents":13,"numAffected":12,"numAtRisk":263},{"groupId":"EG002","numEvents":19,"numAffected":18,"numAtRisk":263},{"groupId":"EG003","numEvents":9,"numAffected":9,"numAtRisk":260},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":133}]},{"term":"Injection site erythema","organSystem":"General disorders","sourceVocabulary":"MedDRA version 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":43,"numAffected":39,"numAtRisk":265},{"groupId":"EG001","numEvents":30,"numAffected":30,"numAtRisk":263},{"groupId":"EG002","numEvents":42,"numAffected":39,"numAtRisk":263},{"groupId":"EG003","numEvents":23,"numAffected":19,"numAtRisk":260},{"groupId":"EG004","numEvents":2,"numAffected":2,"numAtRisk":133}]},{"term":"Injection site pain","organSystem":"General disorders","sourceVocabulary":"MedDRA version 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":198,"numAffected":179,"numAtRisk":265},{"groupId":"EG001","numEvents":215,"numAffected":192,"numAtRisk":263},{"groupId":"EG002","numEvents":212,"numAffected":185,"numAtRisk":263},{"groupId":"EG003","numEvents":192,"numAffected":176,"numAtRisk":260},{"groupId":"EG004","numEvents":19,"numAffected":18,"numAtRisk":133}]},{"term":"Injection site swelling","organSystem":"General disorders","sourceVocabulary":"MedDRA version 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":51,"numAffected":47,"numAtRisk":265},{"groupId":"EG001","numEvents":40,"numAffected":36,"numAtRisk":263},{"groupId":"EG002","numEvents":52,"numAffected":49,"numAtRisk":263},{"groupId":"EG003","numEvents":42,"numAffected":42,"numAtRisk":260},{"groupId":"EG004","numEvents":4,"numAffected":4,"numAtRisk":133}]},{"term":"Pain","organSystem":"General disorders","sourceVocabulary":"MedDRA version 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":34,"numAffected":34,"numAtRisk":265},{"groupId":"EG001","numEvents":23,"numAffected":23,"numAtRisk":263},{"groupId":"EG002","numEvents":30,"numAffected":29,"numAtRisk":263},{"groupId":"EG003","numEvents":33,"numAffected":32,"numAtRisk":260},{"groupId":"EG004","numEvents":2,"numAffected":2,"numAtRisk":133}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA version 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":66,"numAffected":58,"numAtRisk":265},{"groupId":"EG001","numEvents":47,"numAffected":47,"numAtRisk":263},{"groupId":"EG002","numEvents":70,"numAffected":63,"numAtRisk":263},{"groupId":"EG003","numEvents":83,"numAffected":76,"numAtRisk":260},{"groupId":"EG004","numEvents":4,"numAffected":1,"numAtRisk":133}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA version 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":72,"numAffected":47,"numAtRisk":265},{"groupId":"EG001","numEvents":74,"numAffected":41,"numAtRisk":263},{"groupId":"EG002","numEvents":75,"numAffected":50,"numAtRisk":263},{"groupId":"EG003","numEvents":79,"numAffected":53,"numAtRisk":260},{"groupId":"EG004","numEvents":7,"numAffected":4,"numAtRisk":133}]},{"term":"Myalgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA version 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":19,"numAffected":17,"numAtRisk":265},{"groupId":"EG001","numEvents":13,"numAffected":11,"numAtRisk":263},{"groupId":"EG002","numEvents":12,"numAffected":12,"numAtRisk":263},{"groupId":"EG003","numEvents":23,"numAffected":23,"numAtRisk":260},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":133}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA version 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":72,"numAffected":61,"numAtRisk":265},{"groupId":"EG001","numEvents":56,"numAffected":51,"numAtRisk":263},{"groupId":"EG002","numEvents":68,"numAffected":55,"numAtRisk":263},{"groupId":"EG003","numEvents":83,"numAffected":67,"numAtRisk":260},{"groupId":"EG004","numEvents":18,"numAffected":15,"numAtRisk":133}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results. Sponsor review can be expedited to meet publication timelines."},"pointOfContact":{"title":"Senior Vice President, Global Clinical Development","organization":"Merck Sharp & Dohme Corp.","email":"ClinicalTrialsDisclosure@merck.com","phone":"1-800-672-6372"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-11-09","removedCountries":["Canada","Spain","United States"]}},"hasResults":true}